Comparisons
Side-by-side analysis of gene editing technologies, therapies, and biotech companies.
CRISPR-Cas9 vs Base Editing
Compare CRISPR-Cas9 and base editing side by side — mechanism, precision, clinical trials, FDA status, and which is right for different use cases. Updated March 2026.
Gene Therapy vs Gene Editing
Understand the key differences between gene therapy and gene editing — FDA approvals, clinical data, costs ($850K-$4.25M), and which approach is better for different diseases. Updated 2026.
CRISPR Therapeutics vs Intellia Therapeutics
Compare CRISPR Therapeutics (CRSP) and Intellia Therapeutics (NTLA) — Casgevy revenue, in vivo CRISPR progress, market cap, pipeline, and investment outlook. Updated March 2026.
Base Editing vs Prime Editing
Compare base editing and prime editing — NEJM clinical data, PE7 efficiency breakthroughs, edit types, and which next-gen CRISPR tool is better. Updated March 2026.
CRISPR vs TALENs vs Zinc Finger Nucleases
Compare three generations of gene editing — ZFNs (legacy), TALENs (niche), and CRISPR (dominant) — including clinical data, FDA approvals, and why CRISPR won. Updated 2026.
Beam Therapeutics vs Verve Therapeutics
Compare Beam Therapeutics (BEAM) and Verve Therapeutics (now Eli Lilly subsidiary) — pipeline, clinical data, deals, and investment outlook for base editing. Updated March 2026.
Ex Vivo Stem Cell Editing vs In Vivo Gene Therapy
Compare ex vivo stem cell gene editing (Casgevy, Lyfgenia) with in vivo gene therapy (Luxturna, Zolgensma, NTLA-2001). Mechanism, cost, safety, clinical results. Updated 2026.
AAV vs LNP Delivery
Compare AAV (adeno-associated virus) and LNP (lipid nanoparticle) delivery vectors for gene therapy and gene editing — payload size, re-dosing, immunogenicity, cost, and clinical data. Updated 2026.
Intellia vs Beam Therapeutics vs Prime Medicine
Compare Intellia (in vivo CRISPR), Beam (base editing), and Prime Medicine (prime editing) — clinical data, market cap, pipelines, and which gene editing stock to buy. Updated March 2026.
Ex Vivo vs In Vivo Gene Editing
Compare ex vivo gene editing (Casgevy, cells edited outside the body) with in vivo gene editing (Intellia, CRISPR delivered directly into patients). Clinical data, cost, scalability. Updated 2026.
CRISPR vs Epigenetic Editing
Compare CRISPR gene editing (permanent DNA cuts) with epigenetic editing (reversible gene silencing). Tune Therapeutics, mechanism, clinical trials, safety. Updated 2026.
ARKG vs GNOM: Genomics ETFs Compared
Compare ARK Genomic Revolution (ARKG) and Global X Genomics & Biotechnology (GNOM) side-by-side — expense ratios, holdings, performance, and which is right for your portfolio.